SONN

Sonnet Biotherapeutics Holdings Inc

SONN, USA

As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

https://www.sonnetbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SONN
stock
SONN

Sonnet BioTherapeutics (NASDAQ:SONN) Shares Down 67.3% – Here’s Why Defense World

Read more →
SONN
stock
SONN

$SONN Earnings Preview: Recent $SONN Insider Trading, Hedge Fund Activity, and More Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

Target Price:

$20

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.64

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

123.94 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-183.71 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 3.62% of the total shares of Sonnet Biotherapeutics Holdings Inc

1.

Mmcap International Inc. Spc

(1.9567%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4115%)

since

2025/07/31

3.

Geode Capital Management, LLC

(0.3646%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.2899%)

since

2025/07/31

5.

XTX Topco Ltd

(0.2002%)

since

2025/06/30

6.

Cinvest Azero Global FI

(0.1041%)

since

2025/07/31

7.

UBS Group AG

(0.0975%)

since

2025/06/30

8.

Fidelity Total Market Index

(0.0925%)

since

2025/07/31

9.

Fidelity Series Total Market Index

(0.0489%)

since

2025/07/31

10.

Spartan Total Market Index Pool G

(0.0277%)

since

2025/07/31

11.

Tower Research Capital LLC

(0.0215%)

since

2025/06/30

12.

Spartan Extended Market Index Pool F

(0.002%)

since

2025/07/31

13.

NT Ext Equity Mkt Idx Fd - L

(0.0013%)

since

2025/06/30

14.

Northern Trust Extended Eq Market Idx

(0.0013%)

since

2025/06/30

15.

BlackRock Inc

(0.001%)

since

2025/06/30

16.

Carolina Wealth Advisors, LLC

(0.0005%)

since

2025/06/30

17.

Bank of America Corp

(0.0004%)

since

2025/06/30

18.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0004%)

since

2025/06/30

19.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0003%)

since

2024/12/31

20.

Barclays PLC

(0.0002%)

since

2025/03/31

21.

NT Ext Equity Mkt Idx Fd - NL

(0.0001%)

since

2025/06/30

22.

State St US Extended Mkt Indx NL Cl C

(0.0001%)

since

2025/08/31

23.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0001%)

since

2025/06/30

24.

Citigroup Inc

(0%)

since

2025/03/31

25.

Citadel Advisors Llc

(0%)

since

2025/03/31

26.

Two Sigma Investments LLC

(0%)

since

2025/03/31

27.

Virtu Financial LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.95

EPS Estimate

-0.49

EPS Difference

-0.46

Surprise Percent

-93.8776%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.